MSFP
RDHL

Mark Sheptoff Financial Planning’s Redhill Biopharma RDHL Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1
Closed -$6K – 395
2015
Q4 		$6K Hold
1
– – ﹤0.01% 295
2015
Q3 		$6K Buy
+1
New +$14.8K 0.01% 276

Other funds holding RDHL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Mark Sheptoff Financial Planning's RDHL Position: Q1 2016 in Review

Mark Sheptoff Financial Planning sold out of Redhill Biopharma (RDHL) in Q1 2016, closing a stake of 1 share — an estimated $6K sold.

Mark Sheptoff Financial Planning first reported a position in RDHL in Q3 2015 and held it in 2 quarters. The position peaked at $6K in Q4 2015. 21 funds tracked by Wall St. Rank hold RDHL as of Q1 2016.

  • Mark Sheptoff Financial Planning reported no remaining Redhill Biopharma position as of Q1 2016 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 1 Redhill Biopharma share in Q1 2016, an estimated $6K.
  • Mark Sheptoff Financial Planning first reported a position in Redhill Biopharma in Q3 2015 and held it in 2 quarters.
  • Mark Sheptoff Financial Planning's Redhill Biopharma position peaked at $6K in Q4 2015.
  • 21 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2016.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2016, filed 9 May 2016.